151 related articles for article (PubMed ID: 24401984)
1. Growth differentiation factor-15 as biomarker in uterine sarcomas.
Trovik J; Salvesen HB; Cuppens T; Amant F; Staff AC
Int J Gynecol Cancer; 2014 Feb; 24(2):252-9. PubMed ID: 24401984
[TBL] [Abstract][Full Text] [Related]
2. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer.
Staff AC; Trovik J; Eriksson AG; Wik E; Wollert KC; Kempf T; Salvesen HB
Clin Cancer Res; 2011 Jul; 17(14):4825-33. PubMed ID: 21616994
[TBL] [Abstract][Full Text] [Related]
3. Circulating Protein Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas.
Glorie N; Baert T; VAN DEN Bosch T; Coosemans AN
Anticancer Res; 2019 Aug; 39(8):3981-3989. PubMed ID: 31366479
[TBL] [Abstract][Full Text] [Related]
4. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer.
Staff AC; Bock AJ; Becker C; Kempf T; Wollert KC; Davidson B
Gynecol Oncol; 2010 Sep; 118(3):237-43. PubMed ID: 20576287
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel and rapid measurement system for growth differentiation factor-15, progranulin, and osteopontin in uterine sarcoma.
Maeno M; Mizutani T; Tsuyoshi H; Yamada S; Ishikane S; Kawabe S; Nishimura K; Yamada M; Miyamoto K; Yoshida Y
Endocr J; 2020 Jan; 67(1):91-94. PubMed ID: 31534059
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison.
Kim HS; Han KH; Chung HH; Kim JW; Park NH; Song YS; Kang SB
Eur J Surg Oncol; 2010 Jul; 36(7):691-8. PubMed ID: 20570475
[TBL] [Abstract][Full Text] [Related]
7. Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer.
Engerud H; Hope K; Berg HF; Fasmer KE; Tangen IL; Haldorsen IS; Trovik J; Krakstad C
PLoS One; 2019; 14(1):e0210585. PubMed ID: 30645608
[TBL] [Abstract][Full Text] [Related]
8. Analysis of uterine corporeal mesenchymal tumors occurring after menopause.
Ishidera Y; Yoshida H; Oi Y; Katayama K; Miyagi E; Hayashi H; Shigeta H
BMC Womens Health; 2019 Jan; 19(1):13. PubMed ID: 30658711
[TBL] [Abstract][Full Text] [Related]
9. Telomerase activity in needle biopsied uterine myoma-like tumors: differential diagnosis between uterine sarcomas and leiomyomas.
Tsujimura A; Kawamura N; Ichimura T; Honda K; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):361-5. PubMed ID: 11788902
[TBL] [Abstract][Full Text] [Related]
10. A more accurate method to interpret lactate dehydrogenase (LDH) isoenzymes' results in patients with uterine masses.
Di Cello A; Borelli M; Marra ML; Franzon M; D'Alessandro P; Di Carlo C; Venturella R; Zullo F
Eur J Obstet Gynecol Reprod Biol; 2019 May; 236():143-147. PubMed ID: 30925450
[TBL] [Abstract][Full Text] [Related]
11. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions.
Bock AJ; Stavnes HT; Kempf T; Tropè CG; Berner A; Davidson B; Staff AC
Int J Gynecol Cancer; 2010 Dec; 20(9):1448-55. PubMed ID: 21336029
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the predictivity of preoperative serum CA 125 in the differential diagnosis of uterine leiomyoma and uterine sarcoma in the Turkish female population.
Yilmaz N; Sahin I; Kilic S; Ozgu E; Gungor T; Bilge U
Eur J Gynaecol Oncol; 2009; 30(4):412-4. PubMed ID: 19761133
[TBL] [Abstract][Full Text] [Related]
13. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma.
Parker WH; Fu YS; Berek JS
Obstet Gynecol; 1994 Mar; 83(3):414-8. PubMed ID: 8127535
[TBL] [Abstract][Full Text] [Related]
14. Circulating Transcripts and Biomarkers in Uterine Tumors: Is There a Predictive Role?
De Bruyn C; Baert T; Van den Bosch T; Coosemans A
Curr Oncol Rep; 2020 Jan; 22(2):12. PubMed ID: 31997106
[TBL] [Abstract][Full Text] [Related]
15. [Sarcomas and mixed mesodermal tumors of the uterus].
Günthert AR
Ther Umsch; 2011 Oct; 68(10):559-64. PubMed ID: 21968895
[TBL] [Abstract][Full Text] [Related]
16. Research on values of GDF-15 level in the diagnosis of primary liver cancer and evaluation of chemotherapeutic effect.
Shen Y; Zhang ZB; Wu SD; Wu XB; Li J
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(12):3749-3754. PubMed ID: 29949149
[TBL] [Abstract][Full Text] [Related]
17. Differences in the blood serum levels of soluble HLA-G concentrations between the menstrual cycle phases and menopause in patients with ovarian endometriosis and uterine leiomyoma.
Basta P; Mach P; Pitynski K; Bednarek W; Klimek M; Zietek J; Zajac K; Wicherek L
Neuro Endocrinol Lett; 2009 Mar; 30(1):91-8. PubMed ID: 19300397
[TBL] [Abstract][Full Text] [Related]
18. Liquid Biopsy as a Tool for Differentiation of Leiomyomas and Sarcomas of Corpus Uteri.
Dvorská D; Škovierová H; Braný D; Halašová E; Danková Z
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387281
[TBL] [Abstract][Full Text] [Related]
19. [Changes in calprotectin concentration--inflammation marker in serum of women with gynecological cancer].
Mielczarek-Palacz A; Sikora J; Kondera-Anasz Z; Nocoń M
Ginekol Pol; 2011 Nov; 82(11):822-6. PubMed ID: 22384614
[TBL] [Abstract][Full Text] [Related]
20. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Yusuf S; Siegbahn A; Wallentin L
Am Heart J; 2017 Aug; 190():94-103. PubMed ID: 28760218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
